Peptides

Tesamorelin (Egrifta): The FDA-Approved GHRH Peptide — Complete Guide

Medici

29 Apr 2026 — 7 min read

Tesamorelin is one of the most clinically validated peptides in modern medicine — an FDA-approved growth hormone–releasing hormone (GHRH) analog with a growing body of research supporting its use far beyond its original indication. If you've been exploring peptides for body composition, metabolic health, or healthy aging, tesamorelin deserves serious attention.

Unlike many peptides that exist primarily in research or grey-market spaces, tesamorelin has been through the full FDA approval process, with Phase III clinical trials, a published safety profile, and an established prescribing protocol. That clinical pedigree makes it uniquely trustworthy — and increasingly popular in longevity and metabolic medicine clinics.

What Is Tesamorelin?

Tesamorelin is a synthetic analog of human growth hormone–releasing hormone (GHRH), the 44-amino acid peptide your hypothalamus uses to tell your pituitary gland to release growth hormone (GH). The molecule is identical to endogenous GHRH except for a trans-3-hexenoic acid group attached to the N-terminus, which stabilizes it against enzymatic degradation and extends its half-life in circulation.

It was developed by Theratechnologies and received FDA approval in 2010 under the brand name Egrifta for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy — a condition where antiretroviral drugs cause abnormal fat redistribution, particularly visceral fat accumulation.

A newer formulation, Egrifta WR, was approved in March 2025. It delivers the same therapeutic molecule at 1.28 mg per injection with a weekly reconstitution protocol rather than daily, significantly reducing preparation burden for patients.

How Tesamorelin Works: Mechanism of Action

Tesamorelin's mechanism is elegantly physiological. Rather than flooding your system with exogenous growth hormone, it stimulates your pituitary gland's somatotroph cells via GHRH receptors, prompting them to release GH in a natural, pulsatile pattern.

This matters enormously for safety. When GH is released physiologically — in pulses, responding to the body's feedback signals — IGF-1 levels rise in proportion, and when IGF-1 gets high enough, negative feedback signals tell the pituitary to ease off. This built-in regulatory mechanism means you're far less likely to accumulate supraphysiological GH levels compared to directly injecting synthetic HGH.

The downstream cascade works like this:

Tesamorelin binds to GHRH receptors on pituitary somatotroph cells
The pituitary releases GH in pulsatile bursts, preserving the natural rhythm
GH travels to the liver and peripheral tissues
The liver produces insulin-like growth factor-1 (IGF-1)
IGF-1 drives lipolysis (fat breakdown, especially visceral fat), lean mass preservation, collagen synthesis, and cellular repair

In Phase III clinical trials, tesamorelin increased IGF-1 levels by an average of 81% compared to a 5% decrease in the placebo group — a dramatic and clinically meaningful response that underpins virtually all of its benefits.

Clinical Trial Data: What the Research Shows

Tesamorelin's evidence base is exceptional for a peptide. Multiple randomized controlled trials, including a landmark study published in the New England Journal of Medicine by Falutz et al., have characterized its effects in detail.

Visceral Fat Reduction

The headline finding: in the pivotal Phase III trials, tesamorelin reduced visceral adipose tissue (VAT) by 15.2% at 26 weeks, while the placebo group saw a 5.0% increase in the same period. That's a 20+ percentage point separation — statistically and clinically significant.

A 2026 meta-analysis pooling five randomized controlled trials confirmed and expanded on this, finding a mean VAT reduction of 27.71 cm² and an increase in lean body mass of 1.42 kg. Critically, this occurred without meaningful perturbation of glucose metabolism.

Lipid and Metabolic Benefits

Beyond fat redistribution, tesamorelin significantly improved cardiometabolic markers in trials:

Triglycerides decreased by 50 mg/dL in the tesamorelin group vs. a 9 mg/dL increase in placebo
Total cholesterol / HDL ratio improved by 0.31 in treated patients vs. a 0.21 worsening in placebo
IGF-1 increased by 81% vs. a 5% decrease in placebo

Liver Fat (NAFLD/MASLD)

Phase 2 trial data show tesamorelin reduces hepatic fat content. In a 12-month study in NAFLD patients, tesamorelin produced a 32% reduction in liver fat as measured by MRI-PDFF. This is a compelling finding given the growing epidemic of metabolic-associated steatotic liver disease and the limited treatment options available.

Cognitive Function

Perhaps the most surprising research direction: clinical trials evaluating tesamorelin specifically in older adults with mild cognitive impairment found "favorable effects on cognition" — improved executive function and memory versus placebo. Given IGF-1's established roles in neurogenesis, synaptic plasticity, and neuroprotection, the mechanism is plausible. This positions tesamorelin as a tool of interest in longevity medicine for cognitive support.

Tesamorelin Dosing Protocol

The FDA-approved dosing for tesamorelin is 2 mg subcutaneously once daily (standard Egrifta formulation), or 1.28 mg once daily (Egrifta WR, approved 2025). Both deliver equivalent therapeutic outcomes — the WR formulation simply requires weekly rather than daily reconstitution.

For off-label prescribing, clinical protocols generally follow the same 2 mg/day framework with these practical refinements:

Timing: Evening, 30–60 minutes before sleep, on an empty stomach. This aligns with the natural overnight GH pulse and is thought to maximize the lipolytic and anabolic response.
Injection site: Abdomen. Rotate injection sites systematically to minimize tissue reactions.
Course length: Typically 3–6 months, followed by a 4–6 week break for laboratory assessment and re-evaluation.
Cycling: Some longevity protocols use a 5-days-on, 2-days-off pattern to help preserve natural pituitary GHRH receptor sensitivity.

Monitoring While on Tesamorelin

Appropriate monitoring includes:

IGF-1 levels (target mid-normal range for age; avoid supraphysiological elevations)
Fasting glucose and HbA1c
Lipid panel
Waist circumference or DXA scan for body composition changes

Side Effects and Safety Profile

Tesamorelin's safety profile is one of its most compelling attributes — it's documented from a rigorous clinical trial program rather than from anecdote.

The most common adverse effect is injection site reactions — redness, swelling, or mild bruising — reported in approximately 25% of treated patients (versus 14% in placebo). These are generally mild and resolve with proper site rotation.

Tesamorelin vs. Other GH Peptides

Tesamorelin occupies a unique position in the GHRH peptide landscape. Understanding how it compares to alternatives helps clarify when it's the right choice.

Tesamorelin vs. Sermorelin

Sermorelin is the oldest GHRH analog in clinical use, comprising only the first 29 amino acids of GHRH. Its shorter structure means a shorter half-life and typically twice-daily dosing for optimal effect. Tesamorelin's full-length stabilized analog provides a more potent and sustained receptor activation profile. More importantly, tesamorelin has vastly more clinical trial data — sermorelin's evidence base is primarily anecdotal and much of its earlier research was discontinued.

Tesamorelin vs. CJC-1295

CJC-1295 (with DAC) has an extended half-life of 7–10 days due to its albumin-binding modification, enabling weekly injections. However, this continuous, non-pulsatile GH stimulation is physiologically distinct from natural GH release and may progressively blunt the body's regulatory feedback mechanisms. Tesamorelin preserves pulsatile, physiological GH release — arguably more appropriate for long-term use. CJC-1295 also lacks FDA approval and has minimal human clinical data compared to tesamorelin's robust trial program.

Tesamorelin vs. Ipamorelin (and the Stack)

Ipamorelin is a GH secretagogue (GHRP), not a GHRH analog — it works via a completely different receptor pathway (the ghrelin/GHS-R1a receptor). The two are commonly stacked precisely because they act synergistically: tesamorelin primes the pituitary via GHRH receptors while ipamorelin amplifies the GH pulse through a complementary mechanism. Clinics prescribing this combination report enhanced body composition outcomes compared to either peptide alone. Used in isolation, tesamorelin has the stronger targeted evidence base for visceral fat reduction.

Compounding and Access

Tesamorelin is available by prescription through licensed 503A compounding pharmacies for off-label indications. The regulatory environment is currently favorable — the FDA has not designated tesamorelin as a "difficult to compound" substance, placing it in a better position than some other peptides that have faced compounding restrictions.

When evaluating a compounding pharmacy for tesamorelin, look for:

State pharmacy board licensure and PCAB accreditation
USP <797> sterile compounding compliance
Published Certificates of Analysis (COA) for each batch
Mandatory valid prescription from a licensed prescriber

U.S. interest in tesamorelin has surged dramatically. Monthly search volume grew 49% between September 2025 and February 2026 — from roughly 90,500 to over 135,000 monthly searches — reflecting its rapid crossover from HIV specialty medicine into mainstream longevity and metabolic health practice.

Is Tesamorelin Right for You?

Tesamorelin is worth considering for patients who:

Have documented GH axis decline (common with aging, stress, obesity)
Struggle specifically with central/visceral adiposity resistant to diet and exercise
Have metabolic syndrome components (elevated triglycerides, low HDL, hepatic fat)
Are exploring evidence-based longevity interventions with a physician
Want the confidence of FDA-approved clinical data rather than grey-market research

It is less appropriate for younger, healthy individuals without documented GH insufficiency, or for anyone with contraindications including active cancer history.

The Bottom Line

Tesamorelin stands apart from virtually every other peptide in the wellness and longevity space: it has FDA approval, peer-reviewed Phase III clinical trial data published in top journals, a characterized safety profile from rigorous trials, and a growing evidence base for off-label applications including NAFLD, cognitive support, and general metabolic health.

For patients working with qualified prescribers to address visceral adiposity, GH decline, or related metabolic dysfunction, tesamorelin offers a physiologically elegant solution — one that works with your body's own regulatory architecture rather than overriding it. The 2025 approval of Egrifta WR further reduces the practical burden of treatment, making it more accessible than ever.

In a field crowded with under-studied compounds, tesamorelin's clinical pedigree is genuinely exceptional. That's why it's increasingly the anchor peptide in evidence-based metabolic health protocols.

Disclaimer: This article is for informational and educational purposes only. Tesamorelin is a prescription medication. Consult a licensed healthcare provider before beginning any peptide therapy. Nothing here constitutes medical advice.